A phase II, open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Disease site: Prostate cancer
Treatment modality: Radiopharmaceutical, systemic therapy
Status: In follow-up
REASURE is a phase II, multicentre, randomised trial of radium-223 incorporating diffusion-weighted MRI (DW-MRI) and PET imaging with collection of blood, urine and bone marrow samples. REASURE aims to identify potential markers of response to treatment with radium-223 in patients with castration-resistant prostate cancer with bone metastases.
38 patients will be recruited from four UK sites over 18 months. Patients will be randomised to receive a monthly radium-223 injection at a dose of either 50 kBq/kg or 80 kBq/kg for up to 6 months. Patients will be followed up every 4 months for 1 year after their last treatment of radium-223.
Chief Investigator: Professor Chris Parker, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Professor Emma Hall
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Funding: Bayer HealthCare Pharmaceuticals Inc.
View REASURE on the National Institute for Health Research website: NIHR - Be Part Of Research
A plain English summary of the TNT trial is available from Cancer Research UK.
Publications and presentations
There have been no presentations or publications to date.